The Globe and Mail reports in its Thursday, April 25, edition that after a "solid" quarter alongside the release of "industry-leading" 2020 guidance, Canaccord Genuity analyst Matt Bottomley says a premium multiple is justified for Harvest Health & Recreation ($13.49). The Globe's David Leeder writes in the Eye On Equities column that Mr. Bottomley reiterated his "speculative buy" call while raising his share target to $19 from $17. Analysts on average target the shares at $20.50. Mr. Bottomley says in a note: "We would be buyers of HARV at current levels. Harvest announced Q4/18 results that came in a bit ahead of our forecasts on both revenue and adj. EBITDA; however (more importantly), the company also provided pro forma revenue and adj. EBITDA guidance for Q1/19, FY2019 and FY2020, that were all well in excess of our current forecasts (with the high end of FY2020 revenue guidance pegged at US$1-billion). We believe the bullish sentiment from management telegraphs that the company's recent acquisitions are likely tracking well in their respective markets with significant contribution from California and Illinois expected to hit the books (pro forma) next quarter."